Cargando…
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
BACKGROUND: Neutralizing antibodies are approved drugs to treat coronavirus disease-2019 (COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants may reduce the antibody neutralizing activity. New monoclonal antibodies (mAbs) and antibody remolding st...
Autores principales: | Li, Lili, Gao, Meiling, Jiao, Peng, Zu, Shulong, Deng, Yong-qiang, Wan, Dingyi, Cao, Yang, Duan, Jing, Aliyari, Saba R, Li, Jie, Shi, Yueyue, Rao, Zihe, Qin, Cheng-feng, Guo, Yu, Cheng, Genhong, Yang, Heng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113379/ https://www.ncbi.nlm.nih.gov/pubmed/35581593 http://dx.doi.org/10.1186/s13578-022-00794-7 |
Ejemplares similares
-
Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2
por: Li, Lili, et al.
Publicado: (2022) -
ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
por: Li, Lili, et al.
Publicado: (2021) -
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry
por: Zu, Shulong, et al.
Publicado: (2021) -
TRIM22 suppresses Zika virus replication by targeting NS1 and NS3 for proteasomal degradation
por: Zu, Shulong, et al.
Publicado: (2022) -
SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1
por: Zhang, Shilei, et al.
Publicado: (2022)